Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Valeant Pharma, Actavis In Merger Talks : WSJ

RELATED NEWS
Trade VRX now with 
4/27/2013 4:32 AM ET

Canadian drugmaker Valeant Pharmaceuticals International, Inc. (VRX: Quote,VRX.TO: Quote) is said to be in discussions to acquire rival Actavis Inc. (ACT) for over $13 billion, according to the Wall Street Journal.

While the companies were working towards an all-stock deal announcement, few Actavis' directors were against it around the middle of this week. But the executives on both sides are still working to resurrect the deal, the journal added.

In February, Valeant announced that it was in talks to make more acquisitions, and it remains open to discuss a potential "merger of equals". Actavis currently has a market value of nearly $13 billion.

Click here to receive FREE breaking news email alerts for Valeant Pharmaceuticals International and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Starbucks Corp. said Thursday after the markets closed that its second quarter profit rose 9.4% from last year, helped by higher revenue. The company's quarterly earnings per share came in line with analysts' expectations, but its quarterly revenue fell short of analysts' forecast. The world's largest specialty coffee retailer also raised its full year earnings outlook. Software giant Microsoft Corp. said Thursday after the markets closed that its third quarter profit fell 6.6% from last year, when results were boosted by special upgrade offer revenues. However, the company's quarterly earnings per share came in above analysts' expectations as did its quarterly revenue. Apple Inc. said Wednesday after the markets closed that its second quarter profit rose 7% from last year, as sales surged and margins improved amid strong sales of its iPhones. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly revenue. At the same time, the company gave a slightly downbeat revenue forecast for the current quarter.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.